Faster molecule design shortens only the discovery stage, which is a small fraction of the total timeline. The remaining stages are gated by biological and human constraints that computation cannot compress.
What gates each stage
Can be accelerated
- Molecule design: computation and chemistry, parallelizable
- Data analysis: software scales with hardware
Cannot be accelerated by AI
- Preclinical safety testing: animal biology and assessment time
- Recruitment: eligibility, geography, willingness
- Trial follow-up: how long a body takes to respond
- Event accumulation: waiting for enough clinical outcomes
- Regulatory review: careful examination of evidence
Suppose design time falls from three years to three months. If the rest of the path — preclinical work, trial setup, recruitment, the trials, and review — still takes about ten years, the total goes from roughly thirteen years to about ten and a quarter. The saving is real but modest, and it does not change the fact that most of the wait happens after the molecule exists.